On Mar. 20, 2020, Humanigen announced that the company was seeking to conduct a Phase III, randomized, controlled, clinical trial to rapidly advance the clinical development of lenzilumab for the prevention and treatment of cytokine storm which can lead to acute respiratory distress syndrome associated with severe acute respiratory syndrome coronavirus 2 infection in COVID-19.